News

Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic

Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitigation Strategy program. Onco360 will handle specialty dispensing and clinical support for eligible patients as ZENBEXUS enters commercial rollout for an underserved group. The selection of Onco360 for ZENBEXUS distribution comes against...

Tesla, Bank of America and Coca-Cola headline today's research, with growth drivers, investment plans and key risks in focus.

BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.

Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.

Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.

A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.

Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.

BMY vs. ARGX: Which Stock Is the Better Value Option?

Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.

Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.

Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...

Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.

Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.

Novo Nordisk (NVO) will collaborate with artificial intelligence firm Anthropic to help accelerate t

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.